Pure play natural products companyThe evaluation of the diagnostic results is complete and they will no longer invest in the pediatric indication while maintaining the adult opportunity which is already approved and generation revenue. The company is now a pure play natural products company "...spanning cosmeceuticals, nutraceuticals and pharmaceuticals," positioned with near and long-term life growth drivers and the potential to become a global leader in natural-based products for health and wellness.
"We are looking to kick off 2025 with a clear line of sight towards execution of our business plan and believe we are well-positioned for a transformational year.” news release
The oat flour is now generating its first revenue. The beta glucan chewy product should be launched in Q1. PGX should have its first product approved(immune booster; capsule) by Health Canada and on the market by Q2.
The avenanthramide pill has successfully completed Phase I testing with no serious adverse events up to 960mg in the single-ascending dose portion or on the three cohorts of eight subjects two dose portion of the trial. Gilles previously said the higher the dose the more they could treat. Significant understanding of the biomarkers avenanthramide can hit already exists given prior preclinical and clinical data; as well as with the exercise-inflammation study in humans. The Phase IIa portion of the study is expected to begin in Q2 and end in Q3 providing safety/tolerability and preliminary efficacy data in humans. A proof of principle in humans could be achieved.
With Phase I complete and no serious adverse events do we know what dose levels were tested in the multi-dose portion of the trial? What diseases could this level treat given what is know about avenanthramide.
"The Company plans to release a new corporate presentation outlining key development areas and upcoming milestones in January 2025."
Q1 is an important and defining quarter for the company as we could find out important product details and forward plas as well as have a new President and CEO.